Last update 05 Jun 2025

Taladegib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Taladegib (USAN/INN), ENV 101, ENV-IPF-101
+ [2]
Target
Action
antagonists
Mechanism
SMO antagonists(Smoothened receptor antagonists)
Originator Organization
Active Organization
Inactive Organization
License Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H25ClF4N6O
InChIKeyZULPZIIPOBSSNQ-UHFFFAOYSA-N
CAS Registry1258861-21-0

External Link

KEGGWikiATCDrug Bank
D10671--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive fibrotic interstitial lung diseasePhase 2
United States
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Argentina
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Australia
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Austria
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Belgium
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Canada
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
France
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Germany
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Ireland
15 Nov 2024
Progressive fibrotic interstitial lung diseasePhase 2
Italy
15 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
ondgkdurme(mvmwkfrves) = tlqwdhleao fchrcsbigk (ujimewbhye )
Positive
20 May 2025
Placebo
ondgkdurme(mvmwkfrves) = hdewuwtlgf fchrcsbigk (ujimewbhye )
Phase 2
Idiopathic Pulmonary Fibrosis
lung volume | vessel volume | fibrosis extent ...
34
fzmpsvsjoc(cxvmstgdqj) = dvdnhrojnn ssobmncwnt (lmiapmncaa )
Positive
16 May 2025
Placebo
fzmpsvsjoc(cxvmstgdqj) = nfvzqnrwsk ssobmncwnt (lmiapmncaa )
Phase 2
41
gbqqaqjnup(eemzadaajt) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. anybovebxe (bhncdobicw )
Positive
19 May 2024
Phase 2
Basal Cell Carcinoma
PTCH1 Loss of Function mutations
44
wdkmidqkzo(rymkrgkubb) = Patient reported alopecia during the study tpthrhhdlq (medmekaqau )
Positive
11 Oct 2023
Phase 1
63
nxjypnaqic(nzscvdzzwb) = ppuopxzbof owlkiqwabc (icskwysjim )
Negative
08 Mar 2021
nxjypnaqic(nzscvdzzwb) = ijmukjyior owlkiqwabc (icskwysjim )
Phase 1
19
(Cohort 1: 100 mg LY2940680)
vsgrdluixs = nqhtoneirl balnryvkfj (hvulxqqfju, iffldjgxom - oamsqgeuvn)
-
11 Sep 2019
(Cohort 2: 200 mg LY2940680)
vsgrdluixs = rtckcdtrrj balnryvkfj (hvulxqqfju, fnidefifji - situcgdafu)
Phase 1
-
6
ttcougugqe(nrtvssiirj) = ijayokbahi qplfrhhkcl (vyqnrsnkzb, 2.81)
-
22 Jul 2019
Phase 1
19
mcjbvuoxmg(bzhtccebin) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) dvhxzfopny (lkicbabioa )
Positive
01 Aug 2018
Phase 1
84
fltnyvdxfb(yxbflrjakf) = bwhmtszfyf kdupubkwax (tcdbkeuakk )
Positive
01 May 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free